Does Lyrica Withdrawal Cause Seizures?
Yes, abrupt withdrawal from Lyrica (pregabalin) can cause seizures, particularly in patients with a history of epilepsy or those taking high doses. Lyrica acts on calcium channels in the brain to reduce neuronal excitability, and sudden discontinuation disrupts this balance, leading to hyperexcitability that manifests as seizures in some cases.[1][2]
How Common Are Seizures in Lyrica Withdrawal?
Seizures occur in a small subset of patients—reported in post-marketing surveillance and clinical studies at rates under 1% during withdrawal, but higher (up to 3-5%) in epilepsy patients or those on anticonvulsant doses above 300mg/day. Risk rises with rapid tapering; gradual reduction over at least a week minimizes this.[1][3]
What Other Symptoms Come with Lyrica Withdrawal?
Beyond seizures, common symptoms include insomnia, nausea, headache, anxiety, sweating, diarrhea, and mood changes like irritability or depression. These typically start within 24-48 hours of the last dose and peak at 3-5 days, lasting up to 10-14 days. Seizure risk is highest in the first week.[2][4]
Who Is Most at Risk for Seizures?
Patients with seizure disorders, those on Lyrica for epilepsy or neuropathic pain at high doses, or with concurrent use of other CNS depressants face elevated risk. Sudden stops after long-term use (over 6 months) amplify danger; no seizures reported in short-term, low-dose users.[1][3]
How Do Doctors Prevent Withdrawal Seizures?
Guidelines recommend tapering over 1-2 weeks: reduce by 50-75mg daily every 3-7 days, monitoring for symptoms. Hospitalization may be needed for high-risk cases. Restarting Lyrica or switching to gabapentin can control acute withdrawal.[2][4]
What Does the Evidence Say from Studies and FDA Data?
Pfizer's prescribing information lists seizures as a known withdrawal risk based on controlled trials and spontaneous reports. A 2018 review in Therapeutic Advances in Drug Safety analyzed 168 cases, finding seizures in 6%, often alongside status epilepticus. FDA post-marketing data confirms this in epilepsy subsets.[1][5]
[1]: Lyrica Prescribing Information (Pfizer)
[2]: Drugs.com - Lyrica Withdrawal
[3]: FDA Adverse Event Reporting System (FAERS) Summary
[4]: Mayo Clinic - Pregabalin (Oral Route)
[5]: O'Brien et al., Ther Adv Drug Saf (2018), "Pregabalin discontinuation effects." (PubMed: 30151260)